Literature DB >> 8787433

Familial bilateral periventricular nodular heterotopia mimics tuberous sclerosis.

P E Jardine1, M A Clarke, M Super.   

Abstract

A mother and daughter with an initial diagnosis of tuberous sclerosis are described. The daughter presented with partial seizures at the age of 8 months. Computed tomography showed uncalcified periventricular nodules which on magnetic resonance imaging were ovoid, almost contiguous, of grey matter density, and did not enhance with gadolinium. Brain imaging of her asymptomatic mother was similar. Absence of severe mental retardation, extracranial hamartomas, and depigmented patches distinguishes familial bilateral periventricular nodular heterotopia (FNH) from tuberous sclerosis. FNH is probably inherited as an X linked dominant with lethality in males.

Entities:  

Mesh:

Year:  1996        PMID: 8787433      PMCID: PMC1511435          DOI: 10.1136/adc.74.3.244

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  11 in total

1.  Echocardiography and genetic counselling in tuberous sclerosis.

Authors:  D W Webb; R D Thomas; J P Osborne
Journal:  J Med Genet       Date:  1992-07       Impact factor: 6.318

Review 2.  Diagnostic criteria: tuberous sclerosis complex. Report of the Diagnostic Criteria Committee of the National Tuberous Sclerosis Association.

Authors:  E S Roach; M Smith; P Huttenlocher; M Bhat; D Alcorn; L Hawley
Journal:  J Child Neurol       Date:  1992-04       Impact factor: 1.987

3.  Periventricular heterotopia and epilepsy.

Authors:  P R Huttenlocher; S Taravath; S Mojtahedi
Journal:  Neurology       Date:  1994-01       Impact factor: 9.910

4.  Localization of a gene for autosomal dominant nocturnal frontal lobe epilepsy to chromosome 20q 13.2.

Authors:  H A Phillips; I E Scheffer; S F Berkovic; G E Hollway; G R Sutherland; J C Mulley
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

5.  Familial band heterotopias simulating tuberous sclerosis.

Authors:  F J DiMario; R J Cobb; G R Ramsby; C Leicher
Journal:  Neurology       Date:  1993-07       Impact factor: 9.910

6.  Familial periventricular nodular heterotopia.

Authors:  K Kamuro; Y Tenokuchi
Journal:  Brain Dev       Date:  1993 May-Jun       Impact factor: 1.961

7.  Hereditary nodular heterotopia accompanied by mega cisterna magna.

Authors:  T Oda; Y Nagai; S Fujimoto; H Sobajima; M Kobayashi; H Togari; Y Wada
Journal:  Am J Med Genet       Date:  1993-08-15

Review 8.  Subependymal heterotopia: a distinct neuronal migration disorder associated with epilepsy.

Authors:  A A Raymond; D R Fish; J M Stevens; S M Sisodiya; N Alsanjari; S D Shorvon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-10       Impact factor: 10.154

9.  X-linked spastic paraplegia (SPG1), MASA syndrome and X-linked hydrocephalus result from mutations in the L1 gene.

Authors:  M Jouet; A Rosenthal; G Armstrong; J MacFarlane; R Stevenson; J Paterson; A Metzenberg; V Ionasescu; K Temple; S Kenwrick
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

10.  Tuberous sclerosis: a clinicoradiological evaluation of 110 cases with particular reference to atypical presentation.

Authors:  D P Kingsley; B E Kendall; C R Fitz
Journal:  Neuroradiology       Date:  1986       Impact factor: 2.804

View more
  2 in total

1.  A filamin A splice mutation resulting in a syndrome of facial dysmorphism, periventricular nodular heterotopia, and severe constipation reminiscent of cerebro-fronto-facial syndrome.

Authors:  U Hehr; A Hehr; G Uyanik; E Phelan; J Winkler; W Reardon
Journal:  J Med Genet       Date:  2005-11-18       Impact factor: 6.318

2.  Computational analysis of missense filamin-A variants, including the novel p.Arg484Gln variant of two brothers with periventricular nodular heterotopia.

Authors:  Umut Gerlevik; Ceren Saygı; Hakan Cangül; Aslı Kutlu; Erdal Fırat Çaralan; Yasemin Topçu; Nesrin Özören; Osman Uğur Sezerman
Journal:  PLoS One       Date:  2022-05-25       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.